GlassScriptPhysician profile
Elizabeth M Simpson
NPI 1295848794
$23,841.46
in general payments reported to CMS, 2019-2025
33 companies · $7,673 in 2025
The $7,673 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,649 · 2020: $2,101 · 2021: $2,513 · 2022: $2,701 · 2023: $3,018 · 2024: $3,186 · 2025: $7,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,029 · Consulting Fee: $3,825 · Travel and Lodging: $987 · Education: $35.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,029.36 |
| Consulting Fee | $3,825.00 |
| Travel and Lodging | $987.35 |
| Education | $35.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,960.94 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,395.64 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Janssen Biotech, INC. | $1,591.14 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,507.56 | 2019-2025 | |
| Ucb, INC. | $1,315.03 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,278.17 | 2019-2025 | |
| Lilly USA, LLC | $1,233.19 | 2019-2024 | Taltz |
| Horizon Therapeutics Plc | $894.64 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $808.19 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $797.53 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $389.40 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $331.99 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $252.52 | 2019-2023 | Actemra |
| Aurinia Pharma U.S., INC. | $227.02 | 2021-2023 | Lupkynis |
| Pacira Therapeutics, INC. | $224.60 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $217.70 | 2022-2025 | Acthar |
| Sobi, INC | $181.66 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $141.09 | 2019-2025 | Strensiq |
| Celgene Corporation | $133.57 | 2019 | |
| Genzyme Corporation | $133.10 | 2019-2025 | |
| Sandoz INC. | $124.02 | 2023-2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $123.14 | 2023-2024 | Idacio |
| Sanofi-Aventis U.S. LLC | $113.70 | 2019-2020 | |
| Organon LLC | $99.37 | 2023-2025 | Renflexis, Hadlima |
| Ani Pharmaceuticals, INC. | $81.70 | 2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.19 | 2023-2025 | Ofev, Cyltezo |
| Scilex Pharmaceuticals INC. | $48.11 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $43.29 | 2023 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $43.21 | 2023-2024 | Truxima, Simlandi |
| Celltrion USA INC. | $35.38 | 2023 | Yuflyma |
| Mallinckrodt Enterprises LLC | $28.78 | 2019 | |
| Daiichi Sankyo INC. | $11.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.